![]() ![]() The program is made possible by a $200 million USD grant from CEPI, the Coalition for Epidemic Preparedness Initiative.Īmerican Partners: University of Pennsylvania, University of North Carolina, University of California-Davis IVI is a member of a global consortium led by the French-Thai vaccine manufacturer BioNet, alongside Thailand’s Chulalongkorn University and the Universities of Pennsylvania, North Carolina, and California-Davis in the United States, to conduct preclinical studies and clinical trials on a new COVID-19 vaccine. IVI is supporting clinical development of INOVIO’s COVID-19 vaccine candidate by conducting a Phase I/IIa clinical trial at four sites in South Korea to demonstrate tolerability, safety, and immunogenicity. Inovio COVID-19 Vaccine Research & Development Regional Antimicrobial Resistance Data Analysis for advocacy, Response and Policy (RADAAR)Īmerican Partners: Brigham and Women’s Hospital Public Health Surveillance GroupĪmerican Funder: Bill & Melinda Gates FoundationĪmerican Partners: Johns Hopkins University Massachusetts General Hospital University of Maryland Sack, Johns Hopkins Bloomberg School of Public Health (2012-2014) Ongoing IVI-US CollaborationĬapturing Data on Antimicrobial Resistance Patterns and Trends in Use in Regions of Asia (CAPTURA) Ogra, University of Texas/State University of New York (2003-2014)ĭr. John La Montagne, National Institute of Allergy and Infectious Diseases (2001) Longini, Jr., University of Washington (2007-2010)ĭr. ![]() ![]() Tim Endy, Department Chair, SUNY Upstate Medical University (2016) Black, Johns Hopkins Bloomberg School of Public Health (2001- 2014)ĭr. Theodore Tsai, Head of Immunization Science and Policy, Takeda Vaccines (2021- Present) Professor Mathuram Santosham, Johns Hopkins Bloomberg School of Public Health (2016- Present) Nahm, University of Alabama at Birmingham (2001- Present) Professor Myron “Mike” Levine, University of Maryland School of Medicine (2016- Present) Koup, National Institutes of Health (2016- Present) Glass, National Institutes of Health (2016-2020)ĭr. Susan Barnett, Senior Program Officer- HIV Vaccines, Bill & Melinda Gates Foundation (2021- Present)ĭr. Ahonkhai, Gwynedd Consultancy Group LLC (2018- Present) Mandl, Vaccines and Viral Vectors (2018- Present)ĭr. Siber, ClearPath Vaccines (2014-2019)Ĭhairperson Dr. Russell, Johns Hopkins Bloomberg School of Public Health (2003-2007)ĭr. Regina Rabinovich, Bill & Melinda Gates Foundation (2005-2007) George Poste, Arizona State University (2003-2006)ĭr. Mahmoud, Princeton University (2010-2017)ĭr. Joseph Kim, Inovio Pharmaceuticals (2014-2019) Professor Samuel Katz, Duke University Medical Center (2003-2007)ĭr. ![]() Maurice Hilleman, Merck Institute of Therapeutic Research (1995-1996) Glass, National Institutes of Health (2006-2011)ĭr. Chris Varma, Vision Medicines Inc./Frontier Medicines Corporation (2017- Present)Ĭhairperson Professor Barry R. Anthony Ford-Hutchinson, Chief Science Officer, RiboNova Inc. Clemens, Senior Scientific Advisor (IVI Director General 2000-2010)Ĭhairperson George Bickerstaff, CRT Capital Group LLC/M.M. Julia Lynch, M.D., Director of Cholera Programĭr. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |